Table 1.
Laboratory results for the patient
| HBsAg | Anti-HBc | Anti-HBs | Anti-HBc IgM | HBeAg | Anti-HBe | HBV DNA | ALT (IU/L) | AST (IU/L) | |
|---|---|---|---|---|---|---|---|---|---|
| March 2012 (pre-immunization) | neg. | neg. | neg. | 63 (H) | 45 (H) | ||||
| November 2012 (post-immunization) | pos.a | neg.a | neg. | 1.8×109 IU/mL (done a posteriori) | (N) | (N) | |||
| December 2012 | pos.a | neg.a | neg. | 56 (H) | (N) | ||||
| January 2013 | pos. | neg. | neg. | (N) | (N) | ||||
| February 2013 | pos. | neg. | neg. | neg. | pos. | neg. | 3.5×109 IU/mL | (N) | (N) |
| March 2013 | pos. | neg. | neg. | pos. | neg. | 2.6×109 IU/mL | (N) | (N) | |
| June 2013 | pos. | pos. | neg. | pos. | neg. | 2.3×109 IU/mL | 53 (H) | 54 (H) | |
| October 2013 | pos. | pos. | neg. | pos. | neg. | 1.8×109 IU/mL | 81 (H) | 52 (H) | |
| January 2014 | pos. | pos. | pos. (52.7 IU/L) | pos. | neg. | 5.8×108 IU/mL | 65 (H) | 44 (H) | |
| April 2014 | pos. | pos. | pos. (133.5 IU/L) | pos. | neg. | 4.9×108 IU/mL | 44 (H) | 34 (H) | |
| August 2014 | pos. | pos. | pos. (247.0 IU/L) | pos. | neg. | 2.9×108 IU/mL | 43 (H) | 37 (H) | |
| December 2014 (tenofovir started in September 2014) | pos. | pos. | pos. (107.4 IU/L) | pos. | neg. | 1.6×105 IU/mL | (N) | (N) | |
| March 2015 | pos. | pos. | pos. (24.3 IU/L) | pos. | neg. | 5.1×103 IU/mL | (N) | (N) | |
| June 2015 | pos. | pos. | pos. (27.2 IU/L) | pos. | neg. | 7.2×102 IU/mL | (N) | (N) | |
| September 2015 | pos. | pos. | pos. (13.8 IU/L) | pos. | neg. | 7.1×102 IU/mL | (N) | (N) |
Anti-HBe Hepatitis B envelope antibody, ALT alanine aminotransferase, anti-HBc hepatitis B core antibody, anti-HBs hepatitis B surface antibody, AST aspartate aminotransferase, blank no result available, DNA deoxyribonucleic acid, H elevated value, HBeAg Hepatitis B envelope antigen, HBsAg hepatitis B surface antigen, HBV hepatitis B virus, IgM Immunoglobulin M, IU international units, L Litre, mL Millilitre, N normal value, neg. negative, pos. positive
aConfirmed with a second assay